UNSPSC 51351507: Hydroxyprogesterone caproate

This classification denotes a therapeutic progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 276F2O42F5. European Medicines Agency schedules Hydroxyprogesterone caproate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08082MIG. Hydroxyprogesterone caproate generally arises in the molecular formula C27H40O4.

UNSPSC 51351507 Hydroxyprogesterone caproate is a Commodity code encompassing a specific pharmaceutical product supplied through state and local cooperative purchasing agreements and health care facility procurement. State and local governments buy this drug as part of broader generic and branded pharmaceutical contracts distributed through authorized wholesalers to public hospitals, clinics, and health department facilities. Issuing bodies include state health agencies and multistate cooperative purchasing alliances that consolidate demand across participating states and local jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent buyer under this code. Vendors supplying hydroxyprogesterone caproate and related pharmaceuticals must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and carry insurance including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000. Pricing models include flat price, net price formats, or WAC-minus structures; evaluation heavily weights price competitiveness (75 percent) and compliance with administrative fee requirements (5 percent), with a mandatory 3 percent administrative fee on all purchases.

MMCAP's RFP S1070000015802 represents recent activity across Minnesota and Oregon, with a response date of March 26, 2026. The solicitation seeks manufacturers of generic multi-source pharmaceuticals and over-the-counter products to supply comprehensive product catalogs with specific National Drug Codes, SKUs, and packaging configurations. All products must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026 for a two-year term with optional extensions. The RFP does not identify specific set-aside designations or restrictions on responder classifications. Submissions are made through the ePro procurement system with pricing and product data in CSV format; vendors face performance penalties ranging from $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines. The RFP does not disclose specific award values or budget ranges, though vendors should plan for volume-based purchasing across multiple participating state and local health care facilities.